2021
CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort
Akgün KM, Krishnan S, Butt AA, Gibert CL, Graber CJ, Huang L, Pisani MA, Rodriguez-Barradas MC, Hoo GWS, Justice AC, Crothers K, Tate JP. CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort. AIDS 2021, 35: 2355-2365. PMID: 34261095, PMCID: PMC8563390, DOI: 10.1097/qad.0000000000003019.Peer-Reviewed Original Research
2020
Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O’Connor P, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial. Addiction Science & Clinical Practice 2020, 15: 28. PMID: 32727618, PMCID: PMC7388231, DOI: 10.1186/s13722-020-00200-y.Peer-Reviewed Original ResearchConceptsRisk alcohol useAlcohol useAlcohol treatmentHealth of patientsEvidence-based strategiesWeek 24HIV outcomesRoutine careTelephone boosterPhysician managementEnhancement therapyHIVPWHPatientsTrialsTarget populationTreatmentAlcohol-related researchMulti-pronged approachOutcomesParticipantsInsufficient numberTherapyPopulationMethodsInAlcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence?
Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley KA. Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence? AIDS And Behavior 2020, 25: 203-214. PMID: 32617778, PMCID: PMC7775874, DOI: 10.1007/s10461-020-02950-x.Peer-Reviewed Original ResearchConceptsAlcohol useAntiretroviral therapyLow-level alcohol useInitial adherenceAntiretroviral adherenceAdherence interventionsAdherence decreasesAlcohol use increasesScreening scoresLongitudinal associationsAdherencePLWHHIVAnnual changesLinear regression modelsStable scoresRegression modelsScoresSmall annual changesDynamic longitudinal associationsAssociationUse increasesPatientsTherapy
2019
Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial. Journal Of Substance Use And Addiction Treatment 2019, 106: 97-106. PMID: 31540617, PMCID: PMC7244228, DOI: 10.1016/j.jsat.2019.08.007.Peer-Reviewed Original ResearchEffect estimates in randomized trials and observational studies: comparing apples with apples
Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA. Effect estimates in randomized trials and observational studies: comparing apples with apples. American Journal Of Epidemiology 2019, 188: 1569-1577. PMID: 31063192, PMCID: PMC6670045, DOI: 10.1093/aje/kwz100.Peer-Reviewed Original ResearchEmulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systems
2018
Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients
Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, Fiellin DA, Becker WC. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug And Alcohol Dependence 2018, 192: 371-376. PMID: 30122319, PMCID: PMC7106601, DOI: 10.1016/j.drugalcdep.2018.05.033.Peer-Reviewed Original ResearchConceptsLong-term opioid therapyIllicit drug useUrine drug testsDrug useOpioid therapyWhite racePositive urine drug testDrug testsMonths of treatmentElectronic medical recordsWhite patientsChronic painPatient raceMedical recordsPatientsLogistic regressionOpioidsRacial disparitiesDrug testingCocaineCannabisTherapyCliniciansDiscontinuationPain
2017
The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality
Gaither J, Goulet J, Becker W, Crystal S, Edelman E, Gordon K, Kerns R, Rimland D, Skanderson M, Justice A, Fiellin D. The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality. Drug And Alcohol Dependence 2017, 171: e68. DOI: 10.1016/j.drugalcdep.2016.08.196.Peer-Reviewed Original Research
2016
HIV, Aging, and Viral Coinfections: Taking the Long View
Taddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.BooksWhen to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: 214-221. PMID: 26895294, PMCID: PMC4866894, DOI: 10.1097/qai.0000000000000956.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsAntiretroviral therapyCell countAIDS-defining illnessAntiretroviral-naive individualsAIDS Research NetworkMortality hazard ratioHIV-positive personsIntegrated Clinical SystemsHIV-CAUSAL CollaborationVirologic outcomesHIV RNAVirologic failureHazard ratioClinical outcomesProspective studyRisk ratioHigh-income countriesEligible individualsMonths strategyMonthsIllnessDeathTherapy
2015
Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy
Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA, Systems A. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal Of Epidemiology 2015, 45: 2038-2049. PMID: 26721599, PMCID: PMC5841611, DOI: 10.1093/ije/dyv295.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCopies/Antiretroviral Therapy Cohort CollaborationTime-varying covariatesTight control groupAdjusted hazard ratioAntiretroviral therapy regimenAIDS Research NetworkIntegrated Clinical SystemsHIV-CAUSAL CollaborationDeath eventsCohort CollaborationHazard ratioTherapy regimenRandomized trialsInverse probability weightingInclusion criteriaMortality analysisClinical treatmentAIDSTherapyDeath analysisDeathTrialsComparative effectsTrends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV
Becker WC, Gordon K, Jennifer Edelman E, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin DA. Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS And Behavior 2015, 20: 679-686. PMID: 26384973, PMCID: PMC5006945, DOI: 10.1007/s10461-015-1197-5.Peer-Reviewed Original Research
2012
Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States
Ohl ME, Perencevich E, McInnes DK, Kim N, Rimland D, Akgun K, Fiellin DA, Skanderson M, Wang K, Justice A. Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States. AIDS And Behavior 2012, 17: 174-180. PMID: 23080359, DOI: 10.1007/s10461-012-0325-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsConfidence IntervalsFemaleFollow-Up StudiesHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedOdds RatioResidence CharacteristicsRetrospective StudiesRural PopulationSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransConceptsRural-dwelling personsAntiretroviral therapyAntiretroviral adherenceUrban veteransRural-Urban Commuting Area codesVeterans Affairs Healthcare SystemCombination antiretroviral therapyHepatitis C infectionMultivariable logistic regressionSubstance use disordersC infectionHIV infectionRemote residentsHigh adherenceWhite raceVA healthcareUse disordersMedian proportionLogistic regressionAdherenceHealthcare systemRemote settingsTherapyInfectionFace barriers
2011
Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System
Ohl M, Lund B, Belperio PS, Goetz MB, Rimland D, Richardson K, Justice A, Perencevich E, Vaughan-Sarrazin M. Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System. AIDS And Behavior 2011, 17: 250-259. PMID: 22205324, PMCID: PMC5009625, DOI: 10.1007/s10461-011-0107-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCD4 Lymphocyte CountChildChild, PreschoolDelivery of Health CareDiffusion of InnovationFemaleHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHIV Integrase InhibitorsHumansInfantInfant, NewbornMaleMiddle AgedMultivariate AnalysisOdds RatioPatient Acceptance of Health CarePyrrolidinonesRaltegravir PotassiumResidence CharacteristicsRetrospective StudiesRural Health ServicesRural PopulationSurveys and QuestionnairesUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransViral LoadYoung AdultConceptsHIV therapyEqual access healthcare systemNovel HIV therapiesRetrospective cohort studyFirst HIV integrase inhibitorRural-urban variationRaltegravir therapyCohort studyPatient characteristicsMultivariable analysisHIV integrase inhibitorsClinical indicationsRural residenceFDA approvalTherapyIntegrase inhibitorsUrban residenceRural personsHealthcare systemRaltegravirUrban personsDaysRural areasHIVResidenceCritical Illness in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy
Akgün KM, Huang L, Morris A, Justice AC, Pisani M, Crothers K. Critical Illness in HIV-Infected Patients in the Era of Combination Antiretroviral Therapy. Annals Of The American Thoracic Society 2011, 8: 301-307. PMID: 21653532, PMCID: PMC3132789, DOI: 10.1513/pats.201009-060wr.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyAntiretroviral therapyICU admissionCritical illnessAdministration of ARTImpact of ARTProportion of deathsHIV eraOpportunistic infectionsHIVAIDS epidemicMore recent studiesIllnessPatientsAdmissionTherapyRecent studiesICUEtiologyInfectionMortalityIncidenceDiseaseAdministration
2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapyTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDSEffect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal Of Medicine 2009, 360: 1815-1826. PMID: 19339714, PMCID: PMC2854555, DOI: 10.1056/nejmoa0807252.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRisk of deathAsymptomatic patientsHuman immunodeficiency virus (HIV) infectionCubic millimeterEarly-therapy groupImmunodeficiency virus infectionPrevious antiretroviral therapyCohort of patientsClinical characteristicsHIV infectionRelative riskEarly initiationVirus infectionCD4PatientsMedical careTherapyDeathCalendar yearInfectionRiskCountSurvivalGroup
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugsInfluence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment